Notice of Results

Arecor Therapeutics plc

("Arecor" or the "Company")

NOTICE OF RESULTS

Cambridge, UK, 10 April 2025: Arecor Therapeutics plc (AIM: AREC), the biopharmaceutical company advancing today's therapies to enable healthier lives, will announce its audited final results for the year ended 31 December 2024 on Tuesday 22 April 2025.

Sarah Howell, Chief Executive Officer, and David Ellam, Chief Financial Officer, will host an in-person briefing for analysts on the day of the results. There will also be a live webcast and conference call with a Q&A session.

For more details or to attend the briefing, please contact arecor@icrhealthcare.com

-ENDS-

For more information, please contact:

Notes to Editors

About Arecor

Arecor Therapeutics plc is a globally focused biopharmaceutical company transforming patient care by bringing innovative medicines to market through the enhancement of existing therapeutic products. By applying our innovative proprietary technology platform, Arestat™, we are developing an internal portfolio of proprietary products in diabetes and other indications, as well as working with leading pharmaceutical and biotechnology companies to deliver therapeutic products. The Arestat™ platform is supported by an extensive patent portfolio. For further details please see our website, www.arecor.com